Virender Kumar, Ph.D.

About Virender Kumar, Ph.D.

Virender Kumar, Ph.D., With an exceptional h-index of 21 and a recent h-index of 18 (since 2020), a distinguished researcher at University of Nebraska Medical Center, specializes in the field of Drug delivery, Cancer, Immunotherapy, fibrosis, PK/PD.

His recent articles reflect a diverse array of research interests and contributions to the field:

Drug delivery and targeting to chemoresistant pancreatic cancer.

Liquid dosage forms

Gemcitabine elaidate and ONC201 combination therapy for inhibiting pancreatic cancer in a KRAS mutated syngeneic mouse model

Anti-miR-96 and Hh pathway inhibitor MDB5 synergistically ameliorate alcohol-associated liver injury in mice

Targeting BRD4 and PI3K signaling pathways for the treatment of medulloblastoma

Protein and Peptide Delivery to the Lung via Inhalation

Effect of magnesium stearate surface coating method on the aerosol performance and permeability of micronized fluticasone propionate

Ruxolitinib for Treatment of Steroid Refractory Sclerotic Chronic Graft-Versus-Host Disease (cGVHD): Results of a Multicenter Phase II Trial

Virender Kumar, Ph.D. Information

University

Position

___

Citations(all)

1289

Citations(since 2020)

961

Cited By

658

hIndex(all)

21

hIndex(since 2020)

18

i10Index(all)

29

i10Index(since 2020)

28

Email

University Profile Page

Google Scholar

Virender Kumar, Ph.D. Skills & Research Interests

Drug delivery

Cancer

Immunotherapy

fibrosis

PK/PD

Top articles of Virender Kumar, Ph.D.

Title

Journal

Author(s)

Publication Date

Drug delivery and targeting to chemoresistant pancreatic cancer.

Cancer Letters

Virender Kumar

Ram I Mahato

2024/2/2

Liquid dosage forms

Hari R Desu

Ajit S Narang

Virender Kumar

Laura A Thoma

Ram I Mahato

2024/1/1

Gemcitabine elaidate and ONC201 combination therapy for inhibiting pancreatic cancer in a KRAS mutated syngeneic mouse model

Research Square

Ram Mahato

Virender Kumar

Bhartu Sethi

Dalton Staller

2023/7/11

Anti-miR-96 and Hh pathway inhibitor MDB5 synergistically ameliorate alcohol-associated liver injury in mice

Biomaterials

Virender Kumar

Bharti Sethi

Dalton W Staller

Xiaofei Xin

Jingyi Ma

...

2023/4/1

Targeting BRD4 and PI3K signaling pathways for the treatment of medulloblastoma

Journal of Controlled Release

Bharti Sethi

Virender Kumar

Thilina D Jayasinghe

Yuxiang Dong

Donald R Ronning

...

2023/2/1

Protein and Peptide Delivery to the Lung via Inhalation

Xiaofei Xin

Qiyue Wang

Virender Kumar

Ajit S Narang

Ram I Mahato

2022/11/23

Effect of magnesium stearate surface coating method on the aerosol performance and permeability of micronized fluticasone propionate

International journal of pharmaceutics

Virender Kumar

Bharti Sethi

Evelyn Yanez

Dennis H Leung

Yashwardhan Y Ghanwatkar

...

2022/3/5

Ruxolitinib for Treatment of Steroid Refractory Sclerotic Chronic Graft-Versus-Host Disease (cGVHD): Results of a Multicenter Phase II Trial

Blood

Vijaya Raj Bhatt

Valerie K Shostrom

Ayman Saad

Betty K Hamilton

Krishna Gundabolu

...

2022/11/15

Recent advances in drug delivery and targeting to the brain

Bharti Sethi

Virender Kumar

Kalika Mahato

Donald W Coulter

Ram I Mahato

2022/10/1

pH-sensitive nanomedicine of novel tubulin polymerization inhibitor for lung metastatic melanoma

Journal of Controlled Release

Rajan S Bhattarai

Jitender Bariwal

Virender Kumar

Chen Hao

Shanshan Deng

...

2022/10/1

Organ Specific Drug Delivery and Targeting to the Lungs

Ajit S Narang

Ram I Mahato

2022/11/23

Nanoparticle delivery of novel PDE4B inhibitor for the treatment of alcoholic liver disease

Pharmaceutics

Jingyi Ma

Virender Kumar

Ram I Mahato

2022/9/7

Karthik Nagapudi, Ajit S. Narang, and Ram I Mahato

Organ Specific Drug Delivery and Targeting to the Lungs

Rajan S Bhattarai

Virender Kumar

2022/11/23

Polymeric nanomedicine for overcoming resistance mechanisms in hedgehog and Myc-amplified medulloblastoma

Biomaterials

Virender Kumar

Qiyue Wang

Bharti Sethi

Feng Lin

Vinod Kumar

...

2021/11/1

Therapeutic targets, novel drugs, and delivery systems for diabetes associated NAFLD and liver fibrosis

Virender Kumar

Xiaofei Xin

Jingyi Ma

Chalet Tan

Natalia Osna

...

2021/9/1

Activation of dsRNA-dependent protein kinase R by miR-378 sustains metabolic inflammation in hepatic insulin resistance

Diabetes

Hao Wang

Yongyan Song

Yuxin Wu

Virender Kumar

Ram I Mahato

...

2021/3/1

Nanoformulation design and therapeutic potential of a novel tubulin inhibitor in pancreatic cancer

Journal of controlled release

Rajan Sharma Bhattarai

Virender Kumar

Svetlana Romanova

Jitender Bariwal

Hao Chen

...

2021/1/10

Redox-responsive nanoplatform for codelivery of miR-519c and gemcitabine for pancreatic cancer therapy

Science advances

Xiaofei Xin

Virender Kumar

Feng Lin

Vinod Kumar

Rajan Bhattarai

...

2020/11/11

ApoE mimetic peptide targeted nanoparticles carrying a BRD4 inhibitor for treating Medulloblastoma in mice

Journal of controlled release

Qiyue Wang

Virender Kumar

Feng Lin

Bharti Sethi

Donald W Coulter

...

2020/7/10

Functional similarity of modified cascade impactor to deposit drug particles on cells

International journal of pharmaceutics

Virender Kumar

Jitender Bariwal

Ajit S Narang

Jerry Tso

Jonathan Cheong

...

2020/6/15

See List of Professors in Virender Kumar, Ph.D. University(University of Nebraska Medical Center)

Co-Authors

academic-engine